STRATA Skin Sciences (SSKN) 10-Q 11 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 10, 2017
Document And Entity Information
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	1,051,514
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,477,743
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,938	$ 3,928
Accounts receivable, net of allowance for doubtful accounts of $142 and $135, respectively	3,560	3,390
Inventories	3,487	2,817
Prepaid expenses and other current assets	373	617
Total current assets	11,358	10,752
Property and equipment, net	9,396	10,180
Intangible assets, net	13,298	13,412
Goodwill	8,803	8,803
Other assets	47	46
Total assets	42,902	43,193
Current liabilities:
Note payable	137	339
Current portion of long-term debt	3,429	1,714
Accounts payable	2,301	1,853
Other accrued liabilities	2,160	1,992
Deferred revenues	413	235
Total current liabilities	8,440	6,133
Long-term liabilities:
Long-term debt, net	8,150	9,752
Senior secured convertible debentures, net	13,386	12,028
Warrant liability	109	105
Deferred tax liability	479	359
Other liabilities	724	97
Total liabilities	31,288	28,474
Commitment and contingencies
Stockholders' equity:
Preferred Stock, $.10 par value, 10,000,000 shares authorized; 2,928 and 6,000 shares issued and outstanding, respectively	0	1
Common Stock, $.001 par value, 150,000,000 shares authorized; 2,477,743 and 2,166,898 shares issued and outstanding, respectively	3	2
Additional paid-in capital	225,624	225,289
Accumulated deficit	(214,015)	(210,575)
Accumulated other comprehensive income	2	2
Total stockholders' equity	11,614	14,719
Total liabilities and stockholders' equity	$ 42,902	$ 43,193

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Allowance for doubtful accounts	$ 142	$ 135
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	2,928	6,000
Preferred stock, shares outstanding (in shares)	2,928	6,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	2,477,743	2,166,898
Common stock, shares outstanding (in shares)	2,477,743	2,166,898

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract]
Revenues	$ 8,702	$ 7,739	$ 15,974	$ 15,359
Cost of revenues	3,173	3,139	5,906	6,561
Gross profit	5,529	4,600	10,068	8,798
Operating expenses:
Engineering and product development	423	634	898	1,159
Selling and marketing	3,077	3,523	6,227	7,233
General and administrative	1,720	1,901	3,321	4,002
Total operating expenses	5,220	6,058	10,446	12,394
Operating profit (loss) before other income (expense), net	309	(1,458)	(378)	(3,596)
Other income (expense), net:
Interest expense, net	(1,575)	(1,178)	(2,921)	(2,396)
Change in fair value of warrant liability	128	3,199	(4)	5,184
Other income, net	6	(4)	6	(4)
Other income (expense), net	(1,441)	2,017	(2,919)	2,784
(Loss) income before income taxes	(1,132)	559	(3,297)	(812)
Income tax expense	(73)	(61)	(143)	(127)
Net (loss) income	$ (1,205)	$ 498	$ (3,440)	$ (939)
Net (loss) income per share:
Basic (in dollars per share)	$ (0.52)	$ 0.24	$ (1.53)	$ (0.45)
Diluted (in dollars per share)	$ (0.52)	$ (1.17)	$ (1.53)	$ (2.76)
Shares used in computing net (loss) income per share:
Basic (in shares)	2,327,041	2,117,897	2,252,301	2,092,914
Diluted (in shares)	2,327,041	2,311,047	2,252,301	2,216,181

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Preferred Stock [Member]Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2016	$ 1	$ 2	$ 225,289	$ (210,575)	$ 2	$ 14,719
Beginning balance (in shares) at Dec. 31, 2016	6,000	2,166,898
Stock-based compensation	$ 0	$ 0	73	0	0	73
Conversion of senior secured convertible debentures	$ 0	$ 0	262	0	0	262
Conversion of senior secured convertible debentures (in shares)	0	70,000
Conversion of convertible preferred stock	$ (1)	$ 1	0	0	0	0
Conversion of convertible preferred stock (in shares)	(3,072)	239,500
Issuance of common stock for fractional shares in reverse stock split (in shares)		1,345
Net loss	$ 0	$ 0	0	(3,440)	0	(3,440)
Ending balance at Jun. 30, 2017	$ 0	$ 3	$ 225,624	$ (214,015)	$ 2	$ 11,614
Ending balance (in shares) at Jun. 30, 2017	2,928	2,477,743

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows From Operating Activities:
Net loss	$ (3,440)	$ (939)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	3,209	3,323
Provision for doubtful accounts	22	85
Loss on disposal of property, plant and equipment	0	124
Stock-based compensation	73	286
Deferred tax provision	120	120
Amortization of debt discount	1,618	1,239
Amortization of deferred financing costs	115	91
Change in fair value of warrant liability	4	(5,184)
Changes in operating assets and liabilities:
Accounts receivable	(147)	1,275
Inventories	(670)	374
Prepaid expenses and other assets	243	168
Accounts payable	403	(1,834)
Other accrued liabilities	(115)	(686)
Other liabilities	84	(47)
Deferred revenues	178	31
Net cash provided by (used in) operating activities	1,697	(1,574)
Cash Flows From Investing Activities:
Lasers placed-in-service, net	(1,205)	(328)
Purchases of property and equipment, net	(206)	0
Payments on distributor rights liability	(75)	0
Acquisition costs, net of cash received	0	125
Restricted cash	0	15
Net cash used in investing activities	(1,486)	(188)
Cash Flows From Financing Activities:
Proceeds from long-term debt	0	1,500
Payments on notes payable	(201)	(207)
Net cash (used in ) provided by financing activities	(201)	1,293
Effect of exchange rate changes on cash	0	7
Net decrease in cash and cash equivalents	10	(462)
Cash and cash equivalents, beginning of period	3,928	3,303
Cash and cash equivalents, end of period	3,938	2,841
Supplemental information:
Cash paid for interest	1,133	980
Supplemental information of non-cash investing and financing activities:
Conversion of senior secured convertible debentures into common stock	262	248
Recognition of warrants issued as debt discount	0	47
Reclassification of warrant liabilities to equity	0	1,541
Acquisition of distributor rights asset and license liability	$ 900	$ 0

The Company

The Company	6 Months Ended
	Jun. 30, 2017
The Company [Abstract]
The Company	Note 1 The Company: Background STRATA Skin Sciences, Inc. (and its subsidiary) ("STRATA" or "we" or the "Company") is a medical technology company focused on the therapeutic and aesthetic dermatology market. STRATA sales include the following products: XTRAC ® ® The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000 and has since become a recognized treatment among dermatologists. The system delivers targeted 308um ultraviolet light to affected areas of the skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of June 30, 2017, there were 795 XTRAC systems placed in dermatologists' offices in the United States under the Company's recurring revenue business model. The XTRAC systems employed under the recurring revenue model generate revenue on a per procedure basis. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, reimbursement support service and participation in the direct to patient marketing programs employed by the Company. The XTRAC system's use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system. Effective March 1, 2017, the Company entered into an agreement to license the exclusive US distribution rights for the Ellipse family of products, Nordlys, from Ellipse USA ("Ellipse") through December 31, 2019 (the "Initial Term"). If certain sales targets are met, the agreement will automatically be extended for two additional years. Under the terms of the agreement, the Company will be the exclusive distributor of Ellipse lasers. The Company has agreed to minimum inventory purchases and to pay a monthly license fee of approximately $33, in addition to commissions for each system sold. As part of the transaction, the majority of sales and marketing professionals from Ellipse USA became employees of STRATA. The license fee amounts to approximately $1.1 million over the Initial Term. See Note 4 , Intangibles, net , for additional information. Effective February 1, 2017, the Company entered into an exclusive OEM distribution agreement with Esthetic Education, LLC to be the exclusive marketer and seller of private label versions of the SkinStylus MicroSystem and associated parts under the name of STRATAPen. This three-year agreement allows for two one year extensions. Effective April 6, 2017, the Company completed a reverse stock split of its common stock at a ratio of 1-for-5 shares, and all data on common stock and equivalents are shown herein as reflective of this reverse stock split. Liquidity As of June 30, 2017, the Company had an accumulated deficit of $214,015 and had been incurring losses since inception as well as negative cash flows from operations until 2016. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses. Management believes that its cash and cash equivalents as of June 30, 2017 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments, payments of the long-term debt as they become due and other liquidity requirements associated with its existing operations through the next twelve months following the filing of this Form 10-Q. Basis of Presentation Accounting Principles The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. Unaudited interim consolidated financial statements The accompanying interim consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial reporting. These consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to state fairly the consolidated balance sheets, consolidated statements of operations, consolidated statements of cash flows and consolidated statements of stockholders' equity, for the periods presented in accordance with accounting principles generally accepted in the United States ("GAAP"). The consolidated balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017, or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, and other forms filed with the SEC from time to time. Reclassification Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company's financial statements. Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in our 2016 Form 10-K, and there have been no changes to the Company's significant accounting policies during the three and six months ended June 30, 2017. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of June 30, 2017, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and valuation allowances of accounts receivable, (2) the estimated useful lives of intangible assets and property and equipment, (3) the inputs used in determining the fair value of equity-based awards, (4) the valuation allowance related to deferred tax assets and (5) the fair value of financial instruments, including derivative instruments. Fair Value Measurements The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures • Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. • Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. • Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's recurring fair value measurements at June 30, 2017 and December 31, 2016 are as follows: Fair Value as of June 30, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 109 $ - $ - $ 109 Fair Value as of December 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 105 $ - $ - $ 105 The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt (including the current portion) and determined that the fair value of total debt was $21,503 as of June 30, 2017. As of December 31, 2016 the fair value of total debt approximated the recorded value of $20,082. Several of the warrants outstanding as of June 30, 2017 and 2016 have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 8, Warrants Earnings Per Share Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method. For the three and six months ended June 30, 2017, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive. The loss on the change in fair value of the warrant liability was considered when calculating the diluted earnings per share and was deemed to be antidilutive. For the three and six months ended June 30, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability. Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three and six months ended June 30, 2016: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Net income (loss) $ 498 $ (939 ) Gain on the change in fair value of the warrant liability (3,199 ) (5,184 ) Diluted earnings $ (2,701 ) $ (6,123 ) Weighted average number of common and common equivalent shares outstanding: Basic number of common shares outstanding 2,117,897 2,092,914 Dilutive effect of warrants 193,150 123,267 Diluted number of common and common stock equivalent shares outstanding 2,311,047 2,216,181 Potential common stock equivalents outstanding as of June 30, 2017 and 2016 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows: June 30, 2017 2016 Common stock equivalents of convertible debentures 9,146,146 9,221,143 Common stock purchase warrants 2,406,625 3,345,873 Common stock equivalents of convertible preferred stock 228,336 507,173 Common stock options 844,740 601,850 Total 12,625,847 13,676,039 Adoption of New Accounting Standards In January 2017, the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") Clarifying the Definition of a Business Note 4 Intangibles, net In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting The adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes the adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. In July 2015, The FASB issued ASU 2015-11 , Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Recently Issued Accounting Standards In July 2017, the FASB issued a two-part ASU 2017-11, "(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception." For public business entities, the amendments in Part 1 of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 2 of ASU 2017-11 do not require any transition guidance because those amendments do not have an accounting effect. The Company is currently evaluating the impact of this guidance on the Company's condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. The Company is currently evaluating the impact of this guidance on the Company's condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations. In May 2014, The FASB issued ASU 2014-09 , Revenue from Contracts with Customers (Topic 606) We are still evaluating the ASU for other potential impacts on our condensed consolidated financial statements. We currently plan to adopt the ASU using the "modified retrospective" approach, which requires the cumulative effect of initially applying the guidance to be recognized as an adjustment to our accumulated deficit as of the January 1, 2018 adoption date.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventories [Abstract]
Inventories	Note 2 Inventories: June 30 , December 31, 2016 (unaudited) Raw materials and work in progress $ 2,316 $ 2,440 Finished goods 1,171 377 Total inventories $ 3,487 $ 2,817 Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

Property and Equipment, net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2017
Property and Equipment, net [Abstract]
Property and Equipment, net	Note 3 Property and Equipment, net: June 30, 2017 December 31, 2016 (unaudited) Lasers placed-in-service $ 17,828 $ 16,712 Equipment, computer hardware and software 361 160 Furniture and fixtures 111 111 Leasehold improvements 31 25 18,331 17,008 Accumulated depreciation and amortization (8,935 ) (6,828 ) Property and equipment, net $ 9,396 $ 10,180 Depreciation and related amortization expense was $2,195 and $2,415 for the six months ended June 30, 2017 and 2016, respectively.

Intangibles, net

Intangibles, net	6 Months Ended
	Jun. 30, 2017
Intangibles, net [Abstract]
Intangibles, net	Note 4 Intangibles, net: Set forth below is a detailed listing of definite-lived intangible assets: June 30, 2017 December 31, 2016 (unaudited) Core technology $ 5,974 $ 5,974 Product technology 2,000 2,000 Customer relationships 6,900 6,900 Tradenames 1,500 1,500 Distribution rights 900 - 17,274 16,374 Accumulated amortization (3,976 ) (2,962 ) Patents and licensed technologies, net $ 13,298 $ 13,412 Related amortization expense was $1,014 and $908 for the six months ended June 30, 2017 and 2016, respectively. Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows: Remaining 2017 $ 1,066 2018 2,133 2019 2,132 2020 1,615 2021 1,415 Thereafter 4,937 Total $ 13,298 As discussed in Note 1

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Other Accrued Liabilities [Abstract]
Other Accrued Liabilities	Note 5 Other Accrued Liabilities: June 3 0 December 31, 2016 (unaudited) Accrued warranty, current $ 107 $ 102 Accrued compensation, including commissions and vacation 988 1,177 Accrued sales and other taxes 506 439 Distributor rights liability, current 285 - Accrued professional fees and other accrued liabilities 274 274 Total other accrued liabilities $ 2,16 0 $ 1,992

Convertible Debentures

Convertible Debentures	6 Months Ended
	Jun. 30, 2017
Convertible Debentures [Abstract]
Convertible Debentures	Note 6 Convertible Debentures: In the following table is a summary of the Company's convertible debentures. June 30, 2017 December 31, 2016 (unaudited) Senior secured 2.25% convertible debentures, net of unamortized debt discount of $23,007 and $24,314, respectively; and deferred financing costs of $496 and $524, respectively $ 8,247 $ 7,174 Senior secured 4% convertible debentures, net of unamortized debt discount of $3,213 and $3,469, respectively; and deferred financing costs of $363 and $392, respectively 5,139 4,854 Total convertible debt $ 13,386 $ 12,028 The Company issued $32,500 aggregate principal amount of Debentures (the "June 2015 Debentures") that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 8,666,668 shares of Company common stock at an initial conversion price of $3.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance, June 22, 2020. As of June 30, 2017, the cumulative total conversions on the June 2015 Debentures was $750. The June 2015 Debentures include a beneficial conversion feature valued at $27,300 that was recorded as a discount to the debentures. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $3.75 from $6.90, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures are convertible. On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 1,239,769 shares of common stock, $0.001 par value per share, at an exercise price of $12.25 per share expiring in July 2019. The July 2014 Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 1,169,595 shares of common stock at an initial conversion price of $12.825 per share. As of June 30, 2017, the cumulative total conversions on the July 2014 Debentures was $6,285. Note 8, Warrants For financial reporting purposes, the $15,000 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, amounting to $5,296, then to the intrinsic value of the beneficial conversion feature on the July 2014 Debentures of $4,565. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the July 2014 Debentures totaled $10,353 and is being amortized using the effective interest method over the five year life of the July 2014 Debentures. During the six months ended June 30, 2017, the investors converted debentures amounting to $262 into 70,000 shares of common stock for the June 2015 note. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $197 for the six months ended June 30, 2017. As a condition of the new note facility (See Note 7 Long-term Debt On June 6, 2017, the Company entered into a Securities Exchange Agreement (the "Agreement") with the holders of its 2.25% Senior Series A Secured Convertible Debentures due June 30, 2021 and 4% Senior Secured Convertible Debentures due July 30, 2021, pursuant to which the holders have agreed to exchange all of such debentures with an aggregate principal amount of approximately $40,652 into 40,616 shares of newly created Series C Convertible Preferred Stock. In addition to eliminating approximately $40,652 of senior secured debt, the exchange will also eliminate the Company's obligation to pay approximately $4,000 of interest payments over the next four years. The closing of the exchange, and the elimination of such senior debt, will occur within two business days of the approval of the Company's stockholders of the exchange, including the issuance of the shares of common stock issuable upon conversion of the shares of preferred stock, subject to customary closing conditions. The stockholders meeting has been scheduled for September 14, 2017. Other than the limitations on conversions to keep each such holders beneficial ownership below 9.99%, the terms of the Series C Convertible Preferred Stock generally bestow the same rights to each holder as such holder would receive if they are common stock shareholder and are not redeemable by the holders. Each share of Series C Convertible Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69 for a total of approximately 15,099,000 shares of common stock. As of June 30, 2017, the total outstanding amount of Debentures at their face value was $40,465.

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2017
Long-term Debt [Abstract]
Long-term Debt	Note 7 Long-term Debt: June 30, 2017 December 31, 2016 (unaudited) Term note, net of debt discount of $204 and $258, respectively; and deferred financing cost of $217 and $276, respectively $ 11,579 $ 11,466 Less: current portion (3,429 ) (1,714 ) Total long-term debt $ 8,150 $ 9,752 Term-Note Credit Facility On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Agreement") and related financing documents with MidCap Financial Trust ("MidCap") and the lenders listed therein. Under the Agreement, the credit facility may be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The proceeds of this first tranche were used to repay $10,000 principal amount of short-term senior secured promissory notes, plus associated interest, loan fees and expenses. The second tranche was drawn for $1,500 on January 29, 2016. The Company's obligations under the credit facility are secured by a first priority lien on all of the Company's assets. This credit facility includes both financial and non-financial covenants, including a minimum net revenue covenant, beginning in January 2016. The Company is in compliance with these covenants as of June 30, 2017. Interest rate on the credit facility is one month LIBOR plus 8.25%, subject to a LIBOR floor of 0.5% or 9.30% as of June 30, 2017. The Company's existing debentures from its 2014 and 2015 financings were amended as a condition of this new term note facility, including subordination agreements and maturity extensions. As of June 30, 2017 the net balance of long-term debt is $11,579. The following table summarizes the future payments that the Company expects to make for long-term debt for the future periods: Remaining in 2017 $ 1,714 2018 3,429 2019 3,429 2020 3,428 $ 12,000

Warrants

Warrants	6 Months Ended
	Jun. 30, 2017
Warrants [Abstract]
Warrants	Note 8 Warrants: The Company accounts for warrants that require net cash settlement upon change of control of the Company and warrants that have provisions that protect holders from a decline in the issue price of its common stock (or "down-round" provisions) as liabilities instead of equity. The Company recognizes these liabilities at the fair value on each reporting date. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of June 30, 2017 and December 31, 2016 is as follows: June 30, 2017 December 31, 2016 Number of shares underlying the warrants 403,090 403,090 Stock price $ 2.43 $ 2.20 Volatility 47.30 % 47.00 % Risk-free interest rate 1.38 % 1.22 % Expected dividend yield 0 % 0 % Expected warrant life 1.62 – 1.85 years 2.12 – 2.35 years Recurring Level 3 Activity and Reconciliation The tables below provide a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains and losses for the six month periods ended June 30, 2017 and 2016, for all financial liabilities categorized as Level 3 as of June 30, 2017 and June 30, 2016, respectively. Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Issuance Date December 31, 2016 Increase in Fair Value June 30, 2017 10/31/2013 $ 39 $ 2 $ 41 2/5/2014 66 2 68 Total $ 105 $ 4 $ 109 Issuance Date December 31, 2015 Decrease in Fair Value Reclassification to Equity June 30, 2016 10/31/2013 $ 379 $ (267 ) $ - $ 112 2/5/2014 715 (510 ) - 205 7/24/2014 Series A 2,415 (1,573 ) (842 ) - 7/24/2014 Series B 1,726 (1,713 ) (13 ) - 6/22/2015 1,807 (1,121 ) (686 ) - Total $ 7,042 $ (5,184 ) $ (1,541 ) $ 317 Number of Warrants Subject to Remeasurement: Issuance Date June 30, 2017 10/31/2013 137,143 2/5/2014 265,947 Total 403,090

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 9 Stockholders' Equity: Common Stock and Warrants Outstanding common stock warrants consist at June 30, 2017 of the following: Issue Date Expiration Date Total Warrants Exercise Price 4/26/2013 4/26/2018 13,865 $ 55.90 10/31/2013 4/30/2019 137,143 $ 3.75 2/5/2014 2/5/2019 265,947 $ 3.75 7/24/2014 7/24/2019 1,239,769 $ 3.75 - $ 12.25 6/22/2015 6/22/2020 600,000 $ 3.75 12/30/2015 12/30/2020 130,089 $ 5.65 1/29/2016 1/29/2021 19,812 $ 5.30 2,406,625

Stock-based compensation

Stock-based compensation	6 Months Ended
	Jun. 30, 2017
Stock-based compensation [Abstract]
Stock-based compensation	Note 10 Stock-based compensation: At June 30, 2017, the Company had 844,139 options outstanding with a weighted-average exercise price of $4.96. 598,822 options are vested and exercisable. Stock-based compensation expense, primarily included in general and administration, for the three and six months ended June 30, 2017 was $21 and $73, respectively. For the three and six months ended June 30, 2016 stock-based compensation was $116 and $286, respectively. As of June 30, 2017 there was $259 in unrecognized compensation expense, which will be recognized over a weighted average period of 3.0 years.

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2017
Income taxes [Abstract]
Income taxes	Note 11 Income taxes: The Company accounts for income taxes using the asset and liability method for deferred income taxes. The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Income tax expense of $73 and $143 for the three and six months ended June 30, 2017 and $61 and $127 for the three and six months ended June 30, 2016, was comprised primarily of the change in deferred tax liability related to goodwill. Goodwill is an amortizing asset according to tax regulations. This generates a deferred tax liability that is not used to offset deferred tax assets for valuation allowance considerations.

Business Segments and Geographi

Business Segments and Geographic Data	6 Months Ended
	Jun. 30, 2017
Business Segments and Geographic Data [Abstract]
Business Segments and Geographic Data	Note 12 Business Segments and Geographic Data: The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the XTRAC procedures performed by dermatologists. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generated revenues from the sale and usage of imaging devices. The Company has announced that it will no longer support the imaging devices effective September 30, 2017 thus there will be minimal continuing revenues for this segment. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments. The following tables reflect results of operations from our business segments for the periods indicated below: Three Months Ended June 30, 2017 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 6,202 $ 2,496 $ 4 $ 8,702 Costs of revenues 1,843 1,330 - 3,173 Gross profit 4,359 1,166 4 5,529 Gross profit % 70.3 % 46.7 % 100.0 % 63.5 % Allocated operating expenses: Engineering and product development 340 83 - 423 Selling and marketing expenses 2,561 516 - 3,077 Unallocated operating expenses - - - 1,720 2,901 599 - 5,220 Income from operations 1,458 567 4 309 Interest expense, net - - - (1,575 ) Change in fair value of warrant liability - - - 128 Other income, net - - - 6 Income (loss) before income taxes $ 1,458 $ 567 $ 4 $ (1,132 ) Three Months Ended June 30, 2016 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 6,093 $ 1,634 $ 12 $ 7,739 Costs of revenues 2,258 812 69 3,139 Gross profit 3,835 822 ( 57 ) 4,600 Gross profit % 63.0 % 50.3 % (475.0 %) 59.4 % Allocated operating expenses: Engineering and product development 323 54 257 634 Selling and marketing expenses 3,349 96 78 3,523 Unallocated operating expenses - - - 1,901 3,672 150 335 6,058 Income (loss) from operations 163 672 (392 ) (1,458 ) Interest expense, net - - - (1,178 ) Change in fair value of warrant liability - - - 3,199 Other income (expense), net - - - (4 ) Income (loss) before income taxes $ 163 $ 672 $ (392 ) $ 559 Six Months Ended June 30, 2017 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 11,933 $ 4,033 $ 8 $ 15,974 Costs of revenues 3,885 2,021 - 5,906 Gross profit 8,048 2,012 8 10,068 Gross profit % 67.4 % 49.9 % 100.0 % 63.0 % Allocated operating expenses: Engineering and product development 756 141 1 898 Selling and marketing expenses 5,510 717 - 6,227 Unallocated operating expenses - - - 3,321 6,266 858 1 10,446 Income (loss) from operations 1,782 1,154 7 (378 ) Interest expense, net - - - (2,921 ) Change in fair value of warrant liability - - - (4 ) Other income, net - - - 6 Income (loss) before income taxes $ 1,782 $ 1,154 $ 7 $ (3,297 ) Six Months Ended June 30, 2016 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 11,621 $ 3,624 $ 114 $ 15,359 Costs of revenues 4,561 1,764 236 6,561 Gross profit 7,060 1,860 ( 122 ) 8,798 Gross profit % 60.8 % 51.3 % (107.0 %) 57.3 % Allocated operating expenses: Engineering and product development 634 116 409 1,159 Selling and marketing expenses 6,860 203 170 7,233 Unallocated operating expenses - - - 4,002 7,494 319 579 12,394 Income (loss) from operations (434 ) 1,541 (701 ) (3,596 ) Interest expense, net - - - (2,396 ) Change in fair value of warrant liability - - - 5,184 Other income (expense), net - - - (4 ) Income (loss) before income taxes $ (434 ) $ 1,541 $ (701 ) $ (812 ) For the three and six months ended June 30, 2017 and 2016 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Domestic $ 7,086 $ 6,265 $ 13,275 $ 12,158 Foreign 1,616 1,474 2,699 3,201 $ 8,702 $ 7,739 $ 15,974 $ 15,359 Long-lived assets were 100% located in domestic markets as of June 30, 2017 and December 31, 2016.

Significant Customer Concentrat

Significant Customer Concentration	6 Months Ended
	Jun. 30, 2017
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 13 Significant Customer Concentration: For the three months ended June 30, 2017, revenues from sales to the Company's international master distributor (GlobalMed Technologies) were $1,635, or 18.8%, of total revenues for such period. For the six months ended June 30, 2017, revenues from sales to the Company's international master distributor were $2,713, or 17.0%, of total revenues for such period. At June 30, 2017, the accounts receivable balance from GlobalMed Technologies was $681, or 19.1%, of total net accounts receivable. For the three months ended June 30, 2016, revenues from sales to the Company's international master distributor were $1,461, or 18.9%, of total revenues for such period. For the six months ended June 30, 2016, revenues from sales to the Company's international master distributor were $3,147, or 20.5%, of total revenues for such period. No other customer represented more than 10% of total company revenues for the three and six months ended June 30, 2017 and 2016. No other customer represented more than 10% of total accounts receivable as of June 30, 2017.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2017
Related Parties [Abstract]
Related Parties	Note 14 Related Parties: On June 22, 2015, the Company entered into a securities purchase agreement with the Purchasers, including certain funds managed by Sabby Management, LLC and Broadfin Capital LLC (existing Company shareholders), in connection with a private placement. The Purchasers were issued Warrants to purchase an aggregate of 0.6 million shares of common stock, having an exercise price of $3.75 per share. We also issued $32.5 million aggregate principal amount of Debentures that, subject to certain ownership limitations and stockholder approval conditions, were convertible into 8,666,668 shares of common stock at an initial conversion price of $3.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance. Refer to Note 6 In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Debentures and the Warrants pursuant to the terms of the Registration Rights Agreement. In addition to the registration rights, the Selling Stockholders are entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, becoming effective and maintaining an effective registration statement covering the shares underlying the Debentures and the Warrants. The liquidated damages will be payable upon the occurrence of each of those events and each monthly anniversary thereof until cured. The amount of liquidated damages payable is equal to 2.0% of the aggregate purchase price paid by each Purchaser, provided, however, the maximum aggregate liquidated damages payable to a Purchaser shall be 12% of the aggregate subscription amount paid by such Purchaser pursuant to the Purchase Agreement. The liquidated damages shall accrue interest at a rate of 12% per annum (or such lesser maximum amount that is permitted to be paid by applicable law), accruing on a daily basis for each event until such event is cured. The Registration Rights Agreement requires the Company to file one or more registration statements for all of the securities that may be issued upon conversion of the Debentures and exercise of the Warrants issued to the Purchasers. Pursuant to the applicable transaction documents, however, certain Purchasers may not exercise their conversion/exercise rights for that number of shares of common stock which, together with all other shares owned by that Purchaser and its affiliates would result in more than 9.99% of our issued and outstanding shares of common stock calculated on the basis of the then outstanding shares. On June 6, 2017, the Company entered into a Securities Exchange Agreement (the "Agreement") with Broadfin and Sabby, the holders of its 2.25% Senior Series A Secured Convertible Debentures due June 30, 2021 and 4% Senior Secured Convertible Debentures due July 30, 2021, pursuant to which the holders have agreed to exchange all of such debentures with an aggregate principal amount of approximately $40,652 into 40,616 shares of newly created Series C Convertible Preferred Stock. In addition to eliminating approximately $40,652 of senior secured debt, the exchange will also eliminate the Company's obligation to pay approximately $4,000 of interest payments over the next four years. The closing of the exchange, and the elimination of such senior debt, will occur within two business days of the approval of the Company's stockholders of the exchange, including the issuance of the shares of common stock issuable upon conversion of the shares of preferred stock, subject to customary closing conditions. The stockholders meeting has been scheduled for September 14, 2017. Other than the limitations on conversions to keep each such holders beneficial ownership below 9.99%, the terms of the Series C Convertible Preferred Stock generally bestow the same rights to each holder as such holder would receive if they are common stock shareholder and are not redeemable by the holders, except that the Preferred Stock does not have voting rights. Each share of Series C Convertible Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69 for a total of approximately 15,099,000 common stock. On November 4, 2015, the Company entered into consulting agreements with two of its directors, Jeffrey F. O'Donnell, Sr. and Samuel E. Navarro, the terms of which are the same. Under the terms of their respective agreements, each director agrees to provide strategic support, advice and guidance to the Company and its management team in connection with the integration and operation of the expanded business, investor relations and internal and external business development activities. The consultant will make himself available to the Company's President and Chief Executive Officer and the management team on request at mutually convenient times and will report to the Board of Directors quarterly and otherwise when requested by the Board. The agreements had been extended through June 30, 2017. The term of the agreement with Mr. O'Donnell has been further extended through December 31, 2017. Mr. Navarro's agreement expired per its terms on June 30, 2017 and no extensions or renewals of the agreement were entered into. The directors were each to be paid an up-front fee of $40,000 for advice and services rendered prior to the date of the agreement,

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 15 Commitments and Contingencies: Leases The Company has entered into various non-cancelable operating lease agreements for real property and three minor operating leases for personal property. These arrangements expire at various dates through 2019. As of June 30, 2017, aggregate annual minimum payments due under the Company's lease obligations are as follows: Year, 2017 (remaining six months) $ 225 2018 429 2019 160 Total $ 814

The Company (Policies)

The Company (Policies)	6 Months Ended
	Jun. 30, 2017
The Company [Abstract]
Liquidity	Liquidity As of June 30, 2017, the Company had an accumulated deficit of $214,015 and had been incurring losses since inception as well as negative cash flows from operations until 2016. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses. Management believes that its cash and cash equivalents as of June 30, 2017 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments, payments of the long-term debt as they become due and other liquidity requirements associated with its existing operations through the next twelve months following the filing of this Form 10-Q.
Accounting Principles	Accounting Principles The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited interim consolidated financial statements	Unaudited interim consolidated financial statements The accompanying interim consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial reporting. These consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to state fairly the consolidated balance sheets, consolidated statements of operations, consolidated statements of cash flows and consolidated statements of stockholders' equity, for the periods presented in accordance with accounting principles generally accepted in the United States ("GAAP"). The consolidated balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017, or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, and other forms filed with the SEC from time to time.
Reclassification	Reclassification Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company's financial statements.
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in our 2016 Form 10-K, and there have been no changes to the Company's significant accounting policies during the three and six months ended June 30, 2017.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of June 30, 2017, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and valuation allowances of accounts receivable, (2) the estimated useful lives of intangible assets and property and equipment, (3) the inputs used in determining the fair value of equity-based awards, (4) the valuation allowance related to deferred tax assets and (5) the fair value of financial instruments, including derivative instruments.
Fair Value Measurements	Fair Value Measurements The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures • Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. • Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. • Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's recurring fair value measurements at June 30, 2017 and December 31, 2016 are as follows: Fair Value as of June 30, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 109 $ - $ - $ 109 Fair Value as of December 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 105 $ - $ - $ 105 The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt (including the current portion) and determined that the fair value of total debt was $21,503 as of June 30, 2017. As of December 31, 2016 the fair value of total debt approximated the recorded value of $20,082. Several of the warrants outstanding as of June 30, 2017 and 2016 have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 8, Warrants
Earnings Per Share	Earnings Per Share Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method. For the three and six months ended June 30, 2017, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive. The loss on the change in fair value of the warrant liability was considered when calculating the diluted earnings per share and was deemed to be antidilutive. For the three and six months ended June 30, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability. Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three and six months ended June 30, 2016: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Net income (loss) $ 498 $ (939 ) Gain on the change in fair value of the warrant liability (3,199 ) (5,184 ) Diluted earnings $ (2,701 ) $ (6,123 ) Weighted average number of common and common equivalent shares outstanding: Basic number of common shares outstanding 2,117,897 2,092,914 Dilutive effect of warrants 193,150 123,267 Diluted number of common and common stock equivalent shares outstanding 2,311,047 2,216,181 Potential common stock equivalents outstanding as of June 30, 2017 and 2016 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows: June 30, 2017 2016 Common stock equivalents of convertible debentures 9,146,146 9,221,143 Common stock purchase warrants 2,406,625 3,345,873 Common stock equivalents of convertible preferred stock 228,336 507,173 Common stock options 844,740 601,850 Total 12,625,847 13,676,039
Adoption of New Accounting Standards	Adoption of New Accounting Standards In January 2017, the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") Clarifying the Definition of a Business Note 4 Intangibles, net In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting The adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes the adoption of this ASU did not have a significant impact on the condensed consolidated financial statements. In July 2015, The FASB issued ASU 2015-11 , Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company).
Recently Issued Accounting Standards	Recently Issued Accounting Standards In July 2017, the FASB issued a two-part ASU 2017-11, "(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception." For public business entities, the amendments in Part 1 of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 2 of ASU 2017-11 do not require any transition guidance because those amendments do not have an accounting effect. The Company is currently evaluating the impact of this guidance on the Company's condensed consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. The Company is currently evaluating the impact of this guidance on the Company's condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations. In May 2014, The FASB issued ASU 2014-09 , Revenue from Contracts with Customers (Topic 606) We are still evaluating the ASU for other potential impacts on our condensed consolidated financial statements. We currently plan to adopt the ASU using the "modified retrospective" approach, which requires the cumulative effect of initially applying the guidance to be recognized as an adjustment to our accumulated deficit as of the January 1, 2018 adoption date.

The Company (Tables)

The Company (Tables)	6 Months Ended
	Jun. 30, 2017
The Company [Abstract]
Fair Value Measurements on Recurring Basis	The Company's recurring fair value measurements at June 30, 2017 and December 31, 2016 are as follows: Fair Value as of June 30, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 109 $ - $ - $ 109 Fair Value as of December 31, 2016 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Warrant liability (Note 8) $ 105 $ - $ - $ 105
Diluted Earnings Per Common Share Calculated Using Net Loss and Weighted Average Shares Outstanding	Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the three and six months ended June 30, 2016: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Net income (loss) $ 498 $ (939 ) Gain on the change in fair value of the warrant liability (3,199 ) (5,184 ) Diluted earnings $ (2,701 ) $ (6,123 ) Weighted average number of common and common equivalent shares outstanding: Basic number of common shares outstanding 2,117,897 2,092,914 Dilutive effect of warrants 193,150 123,267 Diluted number of common and common stock equivalent shares outstanding 2,311,047 2,216,181
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Potential common stock equivalents outstanding as of June 30, 2017 and 2016 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows: June 30, 2017 2016 Common stock equivalents of convertible debentures 9,146,146 9,221,143 Common stock purchase warrants 2,406,625 3,345,873 Common stock equivalents of convertible preferred stock 228,336 507,173 Common stock options 844,740 601,850 Total 12,625,847 13,676,039

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventories [Abstract]
Schedule of Inventory	June 30 , December 31, 2016 (unaudited) Raw materials and work in progress $ 2,316 $ 2,440 Finished goods 1,171 377 Total inventories $ 3,487 $ 2,817

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2017
Property and Equipment, net [Abstract]
Summary of Property and Equipment, Net	June 30, 2017 December 31, 2016 (unaudited) Lasers placed-in-service $ 17,828 $ 16,712 Equipment, computer hardware and software 361 160 Furniture and fixtures 111 111 Leasehold improvements 31 25 18,331 17,008 Accumulated depreciation and amortization (8,935 ) (6,828 ) Property and equipment, net $ 9,396 $ 10,180

Intangibles, net (Tables)

Intangibles, net (Tables)	6 Months Ended
	Jun. 30, 2017
Intangibles, net [Abstract]
Schedule of Definite-lived Intangible Assets	Set forth below is a detailed listing of definite-lived intangible assets: June 30, 2017 December 31, 2016 (unaudited) Core technology $ 5,974 $ 5,974 Product technology 2,000 2,000 Customer relationships 6,900 6,900 Tradenames 1,500 1,500 Distribution rights 900 - 17,274 16,374 Accumulated amortization (3,976 ) (2,962 ) Patents and licensed technologies, net $ 13,298 $ 13,412
Finite-lived Intangible Assets Amortization Expense	Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows: Remaining 2017 $ 1,066 2018 2,133 2019 2,132 2020 1,615 2021 1,415 Thereafter 4,937 Total $ 13,298

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Other Accrued Liabilities [Abstract]
Schedule of Other Accrued Liabilities	June 3 0 December 31, 2016 (unaudited) Accrued warranty, current $ 107 $ 102 Accrued compensation, including commissions and vacation 988 1,177 Accrued sales and other taxes 506 439 Distributor rights liability, current 285 - Accrued professional fees and other accrued liabilities 274 274 Total other accrued liabilities $ 2,16 0 $ 1,992

Convertible Debentures (Tables)

Convertible Debentures (Tables)	6 Months Ended
	Jun. 30, 2017
Convertible Debentures [Abstract]
Summary of Convertible Debentures	In the following table is a summary of the Company's convertible debentures. June 30, 2017 December 31, 2016 (unaudited) Senior secured 2.25% convertible debentures, net of unamortized debt discount of $23,007 and $24,314, respectively; and deferred financing costs of $496 and $524, respectively $ 8,247 $ 7,174 Senior secured 4% convertible debentures, net of unamortized debt discount of $3,213 and $3,469, respectively; and deferred financing costs of $363 and $392, respectively 5,139 4,854 Total convertible debt $ 13,386 $ 12,028

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Long-term Debt [Abstract]
Long-term Debt	June 30, 2017 December 31, 2016 (unaudited) Term note, net of debt discount of $204 and $258, respectively; and deferred financing cost of $217 and $276, respectively $ 11,579 $ 11,466 Less: current portion (3,429 ) (1,714 ) Total long-term debt $ 8,150 $ 9,752
Summary of Maturities of Long-term Debt	The following table summarizes the future payments that the Company expects to make for long-term debt for the future periods: Remaining in 2017 $ 1,714 2018 3,429 2019 3,429 2020 3,428 $ 12,000

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2017
Warrants [Abstract]
Warrants Fair Value Assumptions	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of June 30, 2017 and December 31, 2016 is as follows: June 30, 2017 December 31, 2016 Number of shares underlying the warrants 403,090 403,090 Stock price $ 2.43 $ 2.20 Volatility 47.30 % 47.00 % Risk-free interest rate 1.38 % 1.22 % Expected dividend yield 0 % 0 % Expected warrant life 1.62 – 1.85 years 2.12 – 2.35 years
Schedule of Warrants Subject to Remeasurement	Number of Warrants Subject to Remeasurement: Issuance Date June 30, 2017 10/31/2013 137,143 2/5/2014 265,947 Total 403,090

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity [Abstract]
Summary of Outstanding Common Stock Warrants	Outstanding common stock warrants consist at June 30, 2017 of the following: Issue Date Expiration Date Total Warrants Exercise Price 4/26/2013 4/26/2018 13,865 $ 55.90 10/31/2013 4/30/2019 137,143 $ 3.75 2/5/2014 2/5/2019 265,947 $ 3.75 7/24/2014 7/24/2019 1,239,769 $ 3.75 - $ 12.25 6/22/2015 6/22/2020 600,000 $ 3.75 12/30/2015 12/30/2020 130,089 $ 5.65 1/29/2016 1/29/2021 19,812 $ 5.30 2,406,625

Business Segments and Geograp32

Business Segments and Geographic Data (Tables)	6 Months Ended
	Jun. 30, 2017
Business Segments and Geographic Data [Abstract]
Schedule of Segment Reporting Information by Segment	The following tables reflect results of operations from our business segments for the periods indicated below: Three Months Ended June 30, 2017 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 6,202 $ 2,496 $ 4 $ 8,702 Costs of revenues 1,843 1,330 - 3,173 Gross profit 4,359 1,166 4 5,529 Gross profit % 70.3 % 46.7 % 100.0 % 63.5 % Allocated operating expenses: Engineering and product development 340 83 - 423 Selling and marketing expenses 2,561 516 - 3,077 Unallocated operating expenses - - - 1,720 2,901 599 - 5,220 Income from operations 1,458 567 4 309 Interest expense, net - - - (1,575 ) Change in fair value of warrant liability - - - 128 Other income, net - - - 6 Income (loss) before income taxes $ 1,458 $ 567 $ 4 $ (1,132 ) Three Months Ended June 30, 2016 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 6,093 $ 1,634 $ 12 $ 7,739 Costs of revenues 2,258 812 69 3,139 Gross profit 3,835 822 ( 57 ) 4,600 Gross profit % 63.0 % 50.3 % (475.0 %) 59.4 % Allocated operating expenses: Engineering and product development 323 54 257 634 Selling and marketing expenses 3,349 96 78 3,523 Unallocated operating expenses - - - 1,901 3,672 150 335 6,058 Income (loss) from operations 163 672 (392 ) (1,458 ) Interest expense, net - - - (1,178 ) Change in fair value of warrant liability - - - 3,199 Other income (expense), net - - - (4 ) Income (loss) before income taxes $ 163 $ 672 $ (392 ) $ 559 Six Months Ended June 30, 2017 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 11,933 $ 4,033 $ 8 $ 15,974 Costs of revenues 3,885 2,021 - 5,906 Gross profit 8,048 2,012 8 10,068 Gross profit % 67.4 % 49.9 % 100.0 % 63.0 % Allocated operating expenses: Engineering and product development 756 141 1 898 Selling and marketing expenses 5,510 717 - 6,227 Unallocated operating expenses - - - 3,321 6,266 858 1 10,446 Income (loss) from operations 1,782 1,154 7 (378 ) Interest expense, net - - - (2,921 ) Change in fair value of warrant liability - - - (4 ) Other income, net - - - 6 Income (loss) before income taxes $ 1,782 $ 1,154 $ 7 $ (3,297 ) Six Months Ended June 30, 2016 (unaudited) Dermatology Recurring Procedures Dermatology Procedures Equipment Dermatology Imaging TOTAL Revenues $ 11,621 $ 3,624 $ 114 $ 15,359 Costs of revenues 4,561 1,764 236 6,561 Gross profit 7,060 1,860 ( 122 ) 8,798 Gross profit % 60.8 % 51.3 % (107.0 %) 57.3 % Allocated operating expenses: Engineering and product development 634 116 409 1,159 Selling and marketing expenses 6,860 203 170 7,233 Unallocated operating expenses - - - 4,002 7,494 319 579 12,394 Income (loss) from operations (434 ) 1,541 (701 ) (3,596 ) Interest expense, net - - - (2,396 ) Change in fair value of warrant liability - - - 5,184 Other income (expense), net - - - (4 ) Income (loss) before income taxes $ (434 ) $ 1,541 $ (701 ) $ (812 )
Schedule of Net Revenues by Geographic Areas	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Domestic $ 7,086 $ 6,265 $ 13,275 $ 12,158 Foreign 1,616 1,474 2,699 3,201 $ 8,702 $ 7,739 $ 15,974 $ 15,359

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Schedule of Approximate Aggregate Minimum Future Payments	As of June 30, 2017, aggregate annual minimum payments due under the Company's lease obligations are as follows: Year, 2017 (remaining six months) $ 225 2018 429 2019 160 Total $ 814

The Company (Details)

The Company (Details) $ in Thousands	Apr. 06, 2017	Jun. 30, 2017USD ($)shares	Jun. 30, 2016USD ($)shares	Jun. 30, 2017USD ($)SystemsExtensionshares	Jun. 30, 2016USD ($)shares	Dec. 31, 2016USD ($)
Business Acquisition [Line Items]
Reverse stock-split ratio	0.20
Liquidity [Abstract]
Accumulated deficit		$ (214,015)		$ (214,015)		$ (210,575)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt		21,503		21,503		20,082
Earnings Per Share [Abstract]
Net income (loss)			$ 498		$ (939)
Gain on the change in fair value of the warrant liability		$ (128)	(3,199)	$ 4	(5,184)
Diluted earnings			$ (2,701)		$ (6,123)
Weighted average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares) | shares		2,327,041	2,117,897	2,252,301	2,092,914
Dilutive effect of warrants (in shares) | shares			193,150		123,267
Diluted number of common and common stock equivalent shares outstanding (in shares) | shares		2,327,041	2,311,047	2,252,301	2,216,181
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				12,625,847	13,676,039
Ellipse [Member]
Business Acquisition [Line Items]
License agreement, number of additional years automatically extended				2 years
Monthly license fee				$ 33
License fee for initial term				$ 1,100
Esthetic Education, LLC [Member]
Business Acquisition [Line Items]
Agreement period				3 years
Number of extensions allowed | Extension				2
Period of extension				1 year
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ 109		$ 109		105
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0		0		0
Fair Value, Measurements, Recurring [Member] | Significant other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0		0		0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ 109		$ 109		$ 105
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices | Systems				795
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				9,146,146	9,221,143
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				2,406,625	3,345,873
Common Stock Equivalents of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				228,336	507,173
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares				844,740	601,850

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Schedule of inventory [Abstract]
Raw materials and work in progress	$ 2,316	$ 2,440
Finished goods	1,171	377
Total inventories	$ 3,487	$ 2,817

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,331		$ 17,008
Accumulated depreciation and amortization	(8,935)		(6,828)
Property and equipment, net	9,396		10,180
Depreciation and related amortization expense	2,195	$ 2,415
Lasers Placed-In-Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,828		16,712
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	361		160
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	111		111
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 31		$ 25

Intangibles, net (Details)

Intangibles, net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 17,274		$ 16,374
Accumulated amortization	(3,976)		(2,962)
Patents and licensed technologies, net	13,298		13,412
Amortization expense of intangible assets	1,014	$ 908
Estimated amortization expense [Abstract]
Remaining 2,017	1,066
2,018	2,133
2,019	2,132
2,020	1,615
2,021	1,415
Thereafter	4,937
Patents and licensed technologies, net	13,298		13,412
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	5,974		5,974
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	2,000		2,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	6,900		6,900
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	1,500		1,500
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 900		$ 0

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Other Accrued Liabilities [Abstract]
Accrued warranty, current	$ 107	$ 102
Accrued compensation, including commissions and vacation	988	1,177
Accrued sales and other taxes	506	439
Distributor rights liability, current	285	0
Accrued professional fees and other accrued liabilities	274	274
Total other accrued liabilities	$ 2,160	$ 1,992

Convertible Debentures (Details

Convertible Debentures (Details) $ / shares in Units, $ in Thousands	Jun. 06, 2017USD ($)shares$ / shares	Jul. 21, 2014USD ($)shares$ / shares	Jun. 30, 2017USD ($)$ / shares	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)shares$ / shares	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)$ / shares
Debt Instrument [Line Items]
Total convertible debt			$ 13,386		$ 13,386		$ 12,028
Aggregate principal amount of debt			$ 40,465		$ 40,465
Common stock, par value (in dollars per share) | $ / shares			$ 0.001		$ 0.001		$ 0.001
Change in fair value of warrant liability			$ (128)	$ (3,199)	$ 4	$ (5,184)
Debentures converted in shares of common stock, value					262	$ 248
Debentures outstanding amount			$ 40,465		$ 40,465
Preferred stock, stated value (in dollars per share) | $ / shares			$ 0.10		$ 0.10		$ 0.10
Senior Secured 2.25% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt			$ 8,247		$ 8,247		$ 7,174
Debt instrument, unamortized discount			23,007		23,007		24,314
Deferred financing costs			$ 496		$ 496		524
Senior secured convertible debentures interest rate			2.25%		2.25%
Aggregate principal amount of debt			$ 32,500		$ 32,500
Number of shares debt convertible (in shares) | shares					8,666,668
Senior secured convertible debentures conversion price (in dollars per share) | $ / shares			$ 3.75		$ 3.75
Maturity period					5 years
Maturity date					Jun. 30, 2021
Debt instruments, cumulative conversions					$ 750
Debt instrument, convertible, beneficial conversion feature					27,300
Debentures outstanding amount			$ 32,500		$ 32,500
Senior Secured 2.25% Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures conversion price (in dollars per share) | $ / shares			$ 6.90		$ 6.90
Senior Secured 2.25% Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures conversion price (in dollars per share) | $ / shares			$ 3.75		$ 3.75
Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt			$ 5,139		$ 5,139		4,854
Debt instrument, unamortized discount		$ 10,353	3,213		3,213		3,469
Deferred financing costs			$ 363		$ 363		$ 392
Senior secured convertible debentures interest rate			4.00%		4.00%
Aggregate principal amount of debt		$ 15,000	$ 15,000		$ 15,000
Number of shares debt convertible (in shares) | shares		1,169,595
Senior secured convertible debentures conversion price (in dollars per share) | $ / shares		$ 12.825
Maturity period					5 years
Maturity date					Jul. 30, 2021
Debt instruments, cumulative conversions					$ 6,285
Debt instrument, convertible, beneficial conversion feature		$ 4,565
Fair value of warrants		5,296
Change in fair value of warrant liability		491
Debt instrument initial carrying amount		4,647
Debentures converted in shares of common stock, value					$ 262
Debt conversion, converted instrument, issued (in shares) | shares					70,000
Interest expense on debt					$ 197
Debentures outstanding amount		$ 15,000	$ 15,000		$ 15,000
Senior Secured 4% Convertible Debentures [Member] | Series A Warrants [Member]
Debt Instrument [Line Items]
Number of warrants to purchase common stock (in shares) | shares		1,239,769
Exercise price of warrants (in dollars per share) | $ / shares		$ 12.25
Common stock, par value (in dollars per share) | $ / shares		$ 0.001
Warrants expiration date					Jul. 31, 2019
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt	$ 40,652
Debentures outstanding amount	40,652
Debt instrument, interest payment	$ 4,000
Number of years for interest payments					4 years
Number of days for approval					2 days
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] | Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares debt convertible (in shares) | shares	15,099,000
Senior secured convertible debentures conversion price (in dollars per share) | $ / shares	$ 2.69
Debt conversion, converted instrument, issued (in shares) | shares	40,616
Preferred stock, stated value (in dollars per share) | $ / shares	$ 1,000
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] | Series C Convertible Preferred Stock [Member] | Maximum [Member]
Debt Instrument [Line Items]
Beneficial ownership percentage	9.99%

Long-term Debt (Details)

Long-term Debt (Details) $ in Thousands	Jan. 29, 2016USD ($)	Dec. 30, 2015USD ($)	Jun. 30, 2017USD ($)Tranche	Dec. 31, 2016USD ($)
Long-term Debt [Abstract]
Less: current portion			$ (3,429)	$ (1,714)
Long-term debt			8,150	9,752
Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Term note, net of debt discount of $204 and $258, respectively; and deferred financing cost of $217 and $276, respectively			11,579	11,466
Less: current portion			(3,429)	(1,714)
Long-term debt			8,150	9,752
Maturities of Long-term Debt [Abstract]
Remaining in 2017			1,714
2,018			3,429
2,019			3,429
2,020			3,428
Total long-term debt			12,000
Unamortized discount on the long term debt			204	258
Deferred financing costs			217	$ 276
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Long-term debt			11,579
Maturities of Long-term Debt [Abstract]
Maximum borrowing capacity under the agreement			$ 12,000
Number of tranches | Tranche			2
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member] | LIBOR [Member]
Maturities of Long-term Debt [Abstract]
Interest rate on credit facility			8.25%
Debt instrument term of variable rate			1 month
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member] | LIBOR [Member] | Minimum [Member]
Maturities of Long-term Debt [Abstract]
LIBOR floor Rate			0.50%
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member] | LIBOR [Member] | Maximum [Member]
Maturities of Long-term Debt [Abstract]
LIBOR floor Rate			9.30%
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member] | First Tranche [Member]
Maturities of Long-term Debt [Abstract]
Proceeds from credit facility		$ 10,500
Repayment of debt		$ (10,000)
MidCap Financial Trust [Member] | Term-Note Credit Facility [Member] | Second Tranche [Member]
Maturities of Long-term Debt [Abstract]
Proceeds from credit facility	$ 1,500

Warrants (Details)

Warrants (Details) - Warrant [Member] - Level 3 [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Fair Value Assumptions [Abstract]
Number of shares underlying the warrants (in shares)	403,090		403,090
Stock price (in dollars per share)	$ 2.43		$ 2.20
Volatility	47.30%		47.00%
Risk-free interest rate	1.38%		1.22%
Expected dividend yield	0.00%		0.00%
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	$ 105	$ 7,042	$ 7,042
Increase (decrease) in fair value	4	(5,184)
Reclassification to Equity		(1,541)
Balance as end of period	$ 109	317	$ 105
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	403,090
Minimum [Member]
Fair Value Assumptions [Abstract]
Expected warrant life	1 year 7 months 13 days		2 years 1 month 13 days
Maximum [Member]
Fair Value Assumptions [Abstract]
Expected warrant life	1 year 10 months 6 days		2 years 4 months 6 days
10/31/2013 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	$ 39	379	$ 379
Increase (decrease) in fair value	2	(267)
Reclassification to Equity		0
Balance as end of period	$ 41	112	39
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	137,143
2/5/2014 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	$ 66	715	715
Increase (decrease) in fair value	2	(510)
Reclassification to Equity		0
Balance as end of period	$ 68	205	66
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	265,947
7/24/2014 Series A [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period		2,415	2,415
Increase (decrease) in fair value		(1,573)
Reclassification to Equity		(842)
Balance as end of period		0
7/24/2014 Series B [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period		1,726	1,726
Increase (decrease) in fair value		(1,713)
Reclassification to Equity		(13)
Balance as end of period		0
6/22/2015 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period		1,807	$ 1,807
Increase (decrease) in fair value		(1,121)
Reclassification to Equity		(686)
Balance as end of period		$ 0

Stockholders' Equity (Details)

Stockholders' Equity (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Class of Warrant or Right [Line Items]
Total Warrants (in shares) | shares	2,406,625
Common Stock Warrant One [Member]
Class of Warrant or Right [Line Items]
Issue Date	Apr. 26, 2013
Expiration Date	Apr. 26, 2018
Total Warrants (in shares) | shares	13,865
Exercise price (in dollars per share) | $ / shares	$ 55.90
Common Stock Warrant Two [Member]
Class of Warrant or Right [Line Items]
Issue Date	Oct. 31, 2013
Expiration Date	Apr. 30, 2019
Total Warrants (in shares) | shares	137,143
Exercise price (in dollars per share) | $ / shares	$ 3.75
Common Stock Warrant Three [Member]
Class of Warrant or Right [Line Items]
Issue Date	Feb. 5, 2014
Expiration Date	Feb. 5, 2019
Total Warrants (in shares) | shares	265,947
Exercise price (in dollars per share) | $ / shares	$ 3.75
Common Stock Warrant Four [Member]
Class of Warrant or Right [Line Items]
Issue Date	Jul. 24, 2014
Expiration Date	Jul. 24, 2019
Total Warrants (in shares) | shares	1,239,769
Common Stock Warrant Four [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 3.75
Common Stock Warrant Four [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 12.25
Common Stock Warrant Five [Member]
Class of Warrant or Right [Line Items]
Issue Date	Jun. 22, 2015
Expiration Date	Jun. 22, 2020
Total Warrants (in shares) | shares	600,000
Exercise price (in dollars per share) | $ / shares	$ 3.75
Common Stock Warrant Six [Member]
Class of Warrant or Right [Line Items]
Issue Date	Dec. 30, 2015
Expiration Date	Dec. 30, 2020
Total Warrants (in shares) | shares	130,089
Exercise price (in dollars per share) | $ / shares	$ 5.65
Common Stock Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Issue Date	Jan. 29, 2016
Expiration Date	Jan. 29, 2021
Total Warrants (in shares) | shares	19,812
Exercise price (in dollars per share) | $ / shares	$ 5.30

Stock-based compensation (Detai

Stock-based compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Number of Stock Options [Roll Forward]
Stock-based compensation expense	$ 21	$ 116	$ 73	$ 286
Unrecognized compensation expense	$ 259		$ 259
Unrecognized compensation expense, weighted average period			3 years
Stock Options [Member]
Number of Stock Options [Roll Forward]
Stock based compensation options outstanding (in shares)	844,139		844,139
Stock based compensation weighted average exercise price (in dollars per share)	$ 4.96		$ 4.96
Stock based compensation vested (in shares)	598,822		598,822
Stock based compensation exercisable (in shares)	598,822		598,822

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income taxes [Abstract]
Income tax expense change in deferred tax liability related to goodwill	$ 73	$ 61	$ 143	$ 127

Business Segments and Geograp45

Business Segments and Geographic Data (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)Segment	Jun. 30, 2016USD ($)	Dec. 31, 2016
Segment Reporting Information [Line Items]
Number of operating segments | Segment			3
Results of Operations from Business Segments [Abstract]
Revenues	$ 8,702	$ 7,739	$ 15,974	$ 15,359
Cost of revenues	3,173	3,139	5,906	6,561
Gross profit	$ 5,529	$ 4,600	$ 10,068	$ 8,798
Gross profit %	63.50%	59.40%	63.00%	57.30%
Allocated operating expenses [Abstract]
Engineering and product development	$ 423	$ 634	$ 898	$ 1,159
Selling and marketing expenses	3,077	3,523	6,227	7,233
Unallocated operating expenses	1,720	1,901	3,321	4,002
Total operating expenses	5,220	6,058	10,446	12,394
Operating profit (loss) before other income (expense), net	309	(1,458)	(378)	(3,596)
Interest expense, net	(1,575)	(1,178)	(2,921)	(2,396)
Change in fair value of warrant liability	128	3,199	(4)	5,184
Other income (expense), net	6	(4)	6	(4)
(Loss) income before income taxes	(1,132)	559	$ (3,297)	(812)
Long Lived Assets [Member] | Geographic Concentration Risk [Member] | Domestic [Member]
Allocated operating expenses [Abstract]
Concentration risk percentage			100.00%		100.00%
Operating Segments [Member] | Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	6,202	6,093	$ 11,933	11,621
Cost of revenues	1,843	2,258	3,885	4,561
Gross profit	$ 4,359	$ 3,835	$ 8,048	$ 7,060
Gross profit %	70.30%	63.00%	67.40%	60.80%
Allocated operating expenses [Abstract]
Engineering and product development	$ 340	$ 323	$ 756	$ 634
Selling and marketing expenses	2,561	3,349	5,510	6,860
Unallocated operating expenses	0	0	0	0
Total operating expenses	2,901	3,672	6,266	7,494
Operating profit (loss) before other income (expense), net	1,458	163	1,782	(434)
Interest expense, net	0	0	0	0
Change in fair value of warrant liability	0	0	0	0
Other income (expense), net	0	0	0	0
(Loss) income before income taxes	1,458	163	1,782	(434)
Operating Segments [Member] | Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	2,496	1,634	4,033	3,624
Cost of revenues	1,330	812	2,021	1,764
Gross profit	$ 1,166	$ 822	$ 2,012	$ 1,860
Gross profit %	46.70%	50.30%	49.90%	51.30%
Allocated operating expenses [Abstract]
Engineering and product development	$ 83	$ 54	$ 141	$ 116
Selling and marketing expenses	516	96	717	203
Unallocated operating expenses	0	0	0	0
Total operating expenses	599	150	858	319
Operating profit (loss) before other income (expense), net	567	672	1,154	1,541
Interest expense, net	0	0	0	0
Change in fair value of warrant liability	0	0	0	0
Other income (expense), net	0	0	0	0
(Loss) income before income taxes	567	672	1,154	1,541
Operating Segments [Member] | Dermatology Imaging [Member]
Results of Operations from Business Segments [Abstract]
Revenues	4	12	8	114
Cost of revenues	0	69	0	236
Gross profit	$ 4	$ (57)	$ 8	$ (122)
Gross profit %	100.00%	(475.00%)	100.00%	(107.00%)
Allocated operating expenses [Abstract]
Engineering and product development	$ 0	$ 257	$ 1	$ 409
Selling and marketing expenses	0	78	0	170
Unallocated operating expenses	0	0	0	0
Total operating expenses	0	335	1	579
Operating profit (loss) before other income (expense), net	4	(392)	7	(701)
Interest expense, net	0	0	0	0
Change in fair value of warrant liability	0	0	0	0
Other income (expense), net	0	0	0	0
(Loss) income before income taxes	4	(392)	7	(701)
Reportable Geographical Components [Member] | Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues	7,086	6,265	13,275	12,158
Reportable Geographical Components [Member] | Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues	$ 1,616	$ 1,474	$ 2,699	$ 3,201

Significant Customer Concentr46

Significant Customer Concentration (Details) - Customer Concentration Risk [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue [Member]
Product Information [Line Items]
Revenues	$ 1,635	$ 1,461	$ 2,713	$ 3,147
Concentration risk percentage	18.80%	18.90%	17.00%	20.50%
Accounts Receivable [Member]
Product Information [Line Items]
Accounts receivable	$ 681		$ 681
Concentration risk percentage			19.10%

Related Parties (Details)

Related Parties (Details) $ / shares in Units, $ in Thousands	Jun. 06, 2017USD ($)shares$ / shares	Nov. 04, 2015USD ($)	Jul. 21, 2014USD ($)shares$ / shares	Jun. 30, 2017USD ($)sharesDirector$ / shares	Dec. 31, 2016$ / shares	Sep. 30, 2015$ / shares
Related Party Transaction [Line Items]
Aggregate principal amount of debt | $				$ 40,465
Preferred stock, stated value (in dollars per share) | $ / shares				$ 0.10	$ 0.10
Number of Directors | Director				2
Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt | $				$ 32,500
Interest rate				2.25%
Number of shares debt convertible (in shares) | shares				8,666,668
Initial conversion price (in dollars per share) | $ / shares				$ 3.75
Maturity period				5 years
Maturity date				Jun. 30, 2021
Senior Secured 2.25% Convertible Debentures [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Initial conversion price (in dollars per share) | $ / shares				$ 6.90
Senior Secured 4% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt | $			$ 15,000	$ 15,000
Interest rate				4.00%
Number of shares debt convertible (in shares) | shares			1,169,595
Initial conversion price (in dollars per share) | $ / shares			$ 12.825
Maturity period				5 years
Maturity date				Jul. 30, 2021
Debt conversion, converted instrument, issued (in shares) | shares				70,000
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt | $	$ 40,652
Debt instrument, interest payment | $	$ 4,000
Number of years for interest payments				4 years
Number of days for approval				2 days
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] | Series C Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares debt convertible (in shares) | shares	15,099,000
Initial conversion price (in dollars per share) | $ / shares	$ 2.69
Debt conversion, converted instrument, issued (in shares) | shares	40,616
Preferred stock, stated value (in dollars per share) | $ / shares	$ 1,000
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] | Series C Convertible Preferred Stock [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Beneficial ownership percentage	9.99%
Sabby Management LLC and Broadfin LLC [Member]
Related Party Transaction [Line Items]
Number of shares underlying warrants (in shares) | shares				600,000
Exercise price of warrants (in dollars per share) | $ / shares				$ 3.75
Percentage of liquidated damages payable				2.00%
Percentage of aggregate liquidated damages payable				12.00%
Interest rate payable on liquidated damages				12.00%
Percentage of issued and outstanding common stock payable upon conversion				9.99%
Sabby Management LLC and Broadfin LLC [Member] | Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt | $				$ 32,500
Interest rate				2.25%
Number of shares debt convertible (in shares) | shares				8,666,668
Initial conversion price (in dollars per share) | $ / shares				$ 3.75		$ 3.75
Maturity period				5 years
Maturity date				Jun. 30, 2021
Two Board Directors [Member]
Related Party Transaction [Line Items]
Up-front fee paid | $		$ 40,000
Monthly retainer fee | $				$ 10,000

Commitments and Contingencies48

Commitments and Contingencies (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)Lease
Commitments and Contingencies [Abstract]
Number of operating leases | Lease	3
Future Annual Minimum Payments under Operating Leases [Abstract]
2017 (remaining six months)	$ 225
2,018	429
2,019	160
Total	$ 814